FIRST EXTENSION - GRANTED
granted
on 12 Sep 2024
Last Applicant/ Owned by
75 Hayden Avenue
Lexington
MA
02421
Serial Number
90458999 filed on 11th Jan 2021
Registration Number
N/A
Correspondent Address
Bridget H. Labutta
Bridget H. Labutta Panitch Schwarze Belisario & Nadel LLP
Two Commerce Square
Philadelphia, PA 19103
United States
Filing Basis
1. intent to use
2. intent to use current
Disclaimer
NO DATA
GALXC PLUS
Research and development of oligonucleotide compounds for use in targeted pharmaceutical therapies for the treatment of rare diseases, genetic disorders, cardiovascular diseases, and viral infections; research and development of pharmaceutical preparations for the treatment of disorders outside the liver; research and development of oligonucleotide compounds for targeted gene silencing; research a Read More
Classification Information
Class [042]
Computer & Software Services & Scientific Services
Research and development of oligonucleotide compounds for use in targeted pharmaceutical therapies for the treatment of rare diseases, genetic disorders, cardiovascular diseases, and viral infections; research and development of pharmaceutical preparations for the treatment of disorders outside the liver; research and development of oligonucleotide compounds for targeted gene silencing; research and development of oligonucleotide drug delivery platforms for use in the treatment of rare diseases, genetic disorders, cardiovascular diseases, and viral infections
First Use Date in General
N/A
First Use Date in Commerce
N/A
Class [005]
Pharmaceutical Products
Oligonucleotide compounds for use in targeted pharmaceutical therapies for the treatment of rare diseases, genetic disorders, cardiovascular diseases, and viral infections; Oligonucleotide delivery agents consisting of compounds that facilitate the delivery of a wide range of pharmaceutical and therapeutic agents intravenously or subcutaneously for use in targeted pharmaceutical therapies for the treatment of rare diseases, genetic disorders, cardiovascular diseases, and viral infections; Oligonucleotide compounds for use in the targeted delivery of RNA interference (RNAi) therapy; Oligonucleotide delivery agents consisting of compounds that facilitate the delivery of a wide range of pharmaceutical and therapeutic agents intravenously or subcutaneously for use in targeted pharmaceutical therapies for a wide range of medical purposes; drug delivery agents consisting of oligonucleotide compounds that facilitate the delivery of a wide range of pharmaceutical based therapies
First Use Date in General
N/A
First Use Date in Commerce
N/A
Mark Details
Serial Number
No 90458999
Mark Type
No Service Mark
Attorney Docket Number
No
44D Filed
No
44D Current
No
44E filed
No
44E Current
No
66A Filed
No
66A Current
No
Current Basis
No
No Basis
No
Legal History
| Status Date | Action Taken |
|---|---|
| 12th Sep 2024 | SOU EXTENSION 1 GRANTED |
| 12th Sep 2024 | SOU EXTENSION 1 FILED |
| 12th Sep 2024 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| 12th Sep 2024 | SOU TEAS EXTENSION RECEIVED |
| 12th Mar 2024 | NOA E-MAILED - SOU REQUIRED FROM APPLICANT |
| 16th Jan 2024 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| 16th Jan 2024 | PUBLISHED FOR OPPOSITION |
| 27th Dec 2023 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| 13th Dec 2023 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| 10th Nov 2023 | TEAS/EMAIL CORRESPONDENCE ENTERED |